Menu

Sangamo

Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies

, , , ,

Cambridge, Mass and Richmond, Calif. –  January 9, 2014 – Biogen Idec (NASDAQ:BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The agreement will enable Biogen Idec to further enhance its […]

Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference

, , ,

RICHMOND, Calif., Jan. 8, 2014 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo’s president and chief executive officer, will present an update on Sangamo’s clinical and preclinical ZFP Therapeutic® programs and upcoming milestones, as well as an overview of the Company’s business strategy at the 32ND AnnualJ.P. Morgan Healthcare Conference on Thursday, January 16TH at 11:00 am PT in San Francisco. “Sangamo […]

Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies

, , ,

Data Presented at American Society of Hematology (ASH) Meeting Demonstrates Therapeutic Levels of Gene Modification in Sangamo’s In Vivo Protein Replacement Platform RICHMOND, Calif., Dec. 10, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new pre-clinical data demonstrating therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. Based […]

Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting

, , ,

Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo’s approach, using its proprietary and highly specific […]

Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment

, , ,

Undetectable Viral Load Sustained Over 20 Weeks in SB-728-902 Study; Data Demonstrate Dose Response in SB-728-1101 Cytoxan Study; Reduction of Viral Reservoir Observed in All Immune Non-Responders Over Three Years RICHMOND, Calif., Dec. 6, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from all dose cohorts in the Company’s ongoing clinical trials (SB-728-1101 […]

Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting

, , ,

RICHMOND, Calif., Nov. 20, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that seven abstracts have been accepted for presentation at the 55TH annual meeting of the American Society of Hematology (ASH), which will be heldDecember 7-10, 2013, in New Orleans, LA. “ASH provides an outstanding forum to highlight our advancing pre-clinical IND-candidate programs,” said Edward Lanphier, Sangamo’s president and CEO. “In particular, […]

Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimer’s Disease Program

, , , ,

Data Demonstrate Long-Term Expression of Functional Nerve Growth Factor in the Brain and Stabilization of Brain Cell Metabolic Activity RICHMOND, Calif., Nov. 15, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for […]

Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic® For Huntington’s Disease

, , ,

Approach Selectively Represses Only the Disease-Causing Gene Resulting in Statistically Significant Effects on Symptoms and Other Biomarkers of Disease in Animal Models RICHMOND, Calif., Nov. 12, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that positive preclinical data from their joint program with Shire plc to develop a novel ZFP Therapeutic® approach to Huntington’s disease (HD) were presented […]

Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection

, , , ,

Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS.  The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects […]

Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia

, , , ,

Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks  Additional Presentations of Preclinical Data at Annual Meeting of European Society of Gene and Cell Therapy (ESGCT) RICHMOND, Calif., Oct. 28, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data demonstrating sustained control of HIV viral load (VL) at […]